{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T08:58:48Z","timestamp":1776848328773,"version":"3.51.2"},"reference-count":36,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2009,11,6]],"date-time":"2009-11-06T00:00:00Z","timestamp":1257465600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.ploscompbiol.org"],"crossmark-restriction":false},"short-container-title":["PLoS Comput Biol"],"DOI":"10.1371\/journal.pcbi.1000557","type":"journal-article","created":{"date-parts":[[2009,11,5]],"date-time":"2009-11-05T17:46:24Z","timestamp":1257443184000},"page":"e1000557","update-policy":"https:\/\/doi.org\/10.1371\/journal.pcbi.corrections_policy","source":"Crossref","is-referenced-by-count":102,"title":["Evolution of Resistance to Targeted Anti-Cancer Therapies during Continuous and Pulsed Administration Strategies"],"prefix":"10.1371","volume":"5","author":[{"given":"Jasmine","family":"Foo","sequence":"first","affiliation":[]},{"given":"Franziska","family":"Michor","sequence":"additional","affiliation":[]}],"member":"340","published-online":{"date-parts":[[2009,11,6]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1309\/5CWPU41AFR1VYM3F","article-title":"Targeted therapies for cancer 2004.","volume":"122","author":"K Ross","year":"2004","journal-title":"Am J Clin Path"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/nature03095","article-title":"Targeted cancer therapy.","volume":"432","author":"C Sawyers","year":"2004","journal-title":"Nature"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to sti-571 cancer therapy caused by bcr-abl gene mutation or amplification.","volume":"293","author":"M Gorre","year":"2001","journal-title":"Science"},{"key":"ref4","first-page":"918","article-title":"Drug-resistant phosphatidylinositol 3-kinase: Guidance for the preemptive strike.","volume":"11","author":"M Burgess","year":"2006","journal-title":"Scientific World Journal"},{"key":"ref5","article-title":"Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the egfr kinase domain.","volume":"2","author":"W Pao","year":"2005","journal-title":"PLoS Medicine"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/sj.onc.1206056","article-title":"Nf-<italic>\u03ba\u03b2<\/italic> transcription factor induces drug resistance through mdr1 expression in cancer cells.","volume":"22","author":"M Bentires-Alj","year":"2003","journal-title":"Oncogene"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S1084-8592(98)80023-4","article-title":"Oncogene expression and cellular radiation resistance: A modulatory role for c-myc.","volume":"3","author":"C Chiang","year":"1998","journal-title":"Mol Diagn"},{"key":"ref8","doi-asserted-by":"crossref","DOI":"10.1007\/978-94-017-2374-9","article-title":"Multiple drug resistance in cancer 2: molecular, cellular and clinical aspects","author":"M Clynes","year":"1998"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1677\/erc.0.0080191","article-title":"Overexpression of her-2 as a resistance mechanism to hormonal therapy for breast cancer.","volume":"8","author":"M Dowsett","year":"2001","journal-title":"Endocr Relat Cancer"},{"key":"ref10","first-page":"4278","article-title":"The ras radiation resistance pathway.","volume":"61","author":"A Gupta","year":"2001","journal-title":"Cancer Res"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"77369","DOI":"10.1038\/sj.onc.1206940","article-title":"The role of glutathione-s-transferase in anticancer drug resistance.","volume":"22","author":"D Townsend","year":"2003","journal-title":"Oncogene"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3233\/BD-2001-14104","article-title":"Dosage parameters in chemotherapy of breast cancer.","volume":"14","author":"W Hryniuk","year":"2001","journal-title":"Breast Disease"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.2165\/00003495-200464170-00001","article-title":"High-dose chemotherapy in breast cancer.","volume":"64","author":"D Lake","year":"2004","journal-title":"Drugs"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1006\/jtbi.2003.3162","article-title":"Minimizing long-term tumor burden: The logic for metronomic chemotherapeutic dosing and its antiangiogenic basis.","volume":"220","author":"P Hahnfeldt","year":"2003","journal-title":"J Theor Biol"},{"key":"ref15","first-page":"1307","article-title":"Tumor size, sensitivity to therapy, and design of treatment schedules.","volume":"61","author":"L Norton","year":"1977","journal-title":"Cancer Treat Rep"},{"key":"ref16","first-page":"163","article-title":"The norton-simon hypothesis revisited.","volume":"70","author":"L Norton","year":"1986","journal-title":"Cancer Treat Rep"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1200\/JCO.2003.09.081","article-title":"Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of intergroup trial c9741\/cancer and leukemia group b trial 9741.","volume":"21","author":"M Citron","year":"2003","journal-title":"J Clin Oncol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0025-5564(83)90087-1","article-title":"Optimal scheduling for cell synchronization by cycle-phase-specific blockers.","volume":"66","author":"B Dibrov","year":"1983","journal-title":"Math Biosci"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1749-6632.1987.tb48738.x","article-title":"The effect of drug schedule on responsiveness to chemotherapy.","volume":"504","author":"Z Agur","year":"1986","journal-title":"Ann Acad New York Sci"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/BF02460591","article-title":"A mathematical model of periodically pulsed chemotherapy: Tumor recurrence and metastasis in a competitive environment.","volume":"58","author":"J Panetta","year":"1996","journal-title":"Bull Math Biol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0025-5564(94)00027-W","article-title":"Drug kinetics and drug resistance in optimal chemotherapy.","volume":"125","author":"M Costa","year":"1995","journal-title":"Math Biosci"},{"key":"ref22","first-page":"1079","article-title":"New tools for cancer chemotherapy: computational assistance for tailoring treatments.","volume":"2","author":"S Gardner","year":"2003","journal-title":"Mol Cancer Therapeutics"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0025-5564(90)90021-P","article-title":"Role of optimal control in chemotherapy.","volume":"101","author":"G Swan","year":"1990","journal-title":"Math Biosci"},{"key":"ref24","article-title":"Optimal control of drug administration in cancer chemotherapy","author":"R Martin","year":"1994"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/BF02459682","article-title":"A stochastic model for the origin and treatment of tumors containing drug-resistant cells.","volume":"48","author":"A Coldman","year":"1986","journal-title":"Bull Math Biol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0025-5564(00)00045-6","article-title":"Optimal control for a stochastic model of cancer chemotherapy.","volume":"168","author":"A Coldman","year":"2000","journal-title":"Math Biosciences"},{"key":"ref27","first-page":"3876","article-title":"Treatment sequencing, asymmetry, and uncertainty: Protocol strategies for combination chemotherapy.","volume":"46","author":"R Day","year":"1986","journal-title":"Cancer Research"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1098\/rspb.2003.2539","article-title":"Evolutionary dynamics of escape from biomedical intervention.","volume":"270","author":"Y Iwasa","year":"2003","journal-title":"Proc Roy Soc Lond B"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"9714","DOI":"10.1073\/pnas.0501870102","article-title":"Drug resistance in cancer: Principles of emergence and prevention.","volume":"102","author":"N Komarova","year":"2005","journal-title":"PNAS"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jtbi.2005.08.003","article-title":"Stochastic modeling of drug resistance in cancer.","volume":"239","author":"N Komarova","year":"2006","journal-title":"J Theor Biol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1534\/genetics.105.049791","article-title":"Evolution of resistance during clonal expansion.","volume":"172","author":"Y Iwasa","year":"2006","journal-title":"Genetics"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1534\/genetics.107.078915","article-title":"The evolution of two mutations during clonal expansion.","volume":"177","author":"H Haeno","year":"2007","journal-title":"Genetics"},{"key":"ref33","article-title":"Branching processes","author":"K Athreya","year":"2004"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1200\/JCO.2001.19.13.3267","article-title":"Phase I and pharmacologic study of osi-774, and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies.","volume":"19","author":"M Hidalgo","year":"2001","journal-title":"Journal of Clinical Oncology"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1200\/JCO.2004.06.075","article-title":"Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck.","volume":"11","author":"D Soulieres","year":"2004","journal-title":"Journal of Clinical Oncology"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/cncr.22088","article-title":"A phase I\/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer.","volume":"107","author":"D Milton","year":"2006","journal-title":"Cancer"}],"updated-by":[{"DOI":"10.1371\/annotation\/d5844bf3-a6ed-4221-a7ba-02503405cd5e","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2009,12,23]],"date-time":"2009-12-23T00:00:00Z","timestamp":1261526400000}}],"container-title":["PLoS Computational Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pcbi.1000557","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,22]],"date-time":"2018-10-22T14:04:25Z","timestamp":1540217065000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1000557"}},"subtitle":[],"editor":[{"given":"Donna K.","family":"Slonim","sequence":"first","affiliation":[]}],"short-title":[],"issued":{"date-parts":[[2009,11,6]]},"references-count":36,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2009,11,6]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pcbi.1000557","relation":{"correction":[{"id-type":"doi","id":"10.1371\/annotation\/d5844bf3-a6ed-4221-a7ba-02503405cd5e","asserted-by":"object"}]},"ISSN":["1553-7358"],"issn-type":[{"value":"1553-7358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,11,6]]}}}